Imricor Medical Systems (ASX:IMR): MRI-Guided Cardiac Technology and U.S. Commercial Expansion

Aditi Sarkar

21 October 2026 03:23 PM AEDT

Imricor Medical Systems (ASX:IMR): MRI-Guided Cardiac Technology and U.S. Commercial Expansion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Imricor Medical Systems (ASX:IMR) reported Q2 CY2026 revenue of USD 60,500.
Q2 net loss was approximately USD 7.4 million, while operating cash outflow was USD 6.1 million.
A AUD 60 million placement supported the company’s expansion and clinical programs.
Rady Children’s Hospital–San Diego became its first commercial U.S. hospital customer.

Imricor Medical Systems, Inc. develops magnetic resonance (MR)-compatible devices used in image-guided cardiovascular interventions. Its latest developments include U.S. regulatory clearances, a first commercial U.S. hospital customer and additional clinical studies. Imricor Medical Systems (ASX:IMR) was quoted at AUD 1.33, down 3.27%, in the share-price figures presented for this 21 October 2026 article; a separate trading-session date was not identified in those figures.

Company Business

The U.S.-based medical technology company makes equipment and single-use instruments designed for procedures performed under real-time magnetic resonance imaging, rather than conventional X-ray fluoroscopy. Its portfolio includes the NorthStar mapping and guidance system, Advantage-MR electrophysiology recorder and stimulator, Vision-MR catheters, and introducers and sheaths. These products address cardiac catheterisation and electrophysiology applications.

The approach aims to provide anatomical and tissue information during procedures without procedure-related ionising radiation. Clinical adoption depends on compatible MR facilities, clinician training, product approvals and hospital purchasing decisions. Imricor Medical Systems (ASX:IMR) has commercial and clinical activity in Europe and the United States, alongside initiatives in the Middle East. Product authorisations and permitted uses differ among jurisdictions.

Recent Development

In September 2026, Imricor announced Rady Children’s Hospital–San Diego as its first commercial U.S. hospital customer. The hospital plans to establish an MR-guided cardiac catheterisation program using NorthStar. The announcement followed the launch of the Imricor Cardiovascular business line in August, broadening the company’s commercial focus beyond electrophysiology ablation.

In July, U.S. FDA 510(k) clearances extended the permitted use of NorthStar and the Vision-MR Diagnostic Catheter to paediatric patients. Earlier clearances established initial U.S. use for these products. Other components of the company’s electrophysiology platform remain subject to their own regulatory processes, so individual product clearances should not be interpreted as approval of the complete platform.

Imricor Medical Systems (ASX:IMR) also announced an interventional MR laboratory solution with Philips in August, combining Philips 1.5-tesla imaging technology with Imricor systems and consumables. Compatibility testing and equipment integration are important for moving potential customer sites toward installation. The company continues the VISABL-AFL trial and the VISABL-VT trial involving MR-guided cardiac ablation.

Financial Performance and Sector Context

For the quarter ended 30 June 2026, revenue was USD 60,500. The company attributed part of the low consumable sales volume to clinical trial procedures for which devices are not recognised as revenue. This distinction matters when evaluating commercial sales separately from research activity.

The quarterly net loss was approximately USD 7.4 million. Clinical trial expenditure, product development and commercial investment were among the cost pressures. Operating cash outflow was USD 6.1 million, compared with USD 7.9 million in the March 2026 quarter.

At 30 June 2026, cash and short-term investments totalled USD 67.5 million. Post-period exercises of options raised approximately USD 2.1 million, yielding a pro forma balance of about USD 69.6 million, which is not the reported balance-date figure. Imricor Medical Systems (ASX:IMR) also completed a AUD 60 million institutional placement in May 2026 at AUD 1.85 per CDI.

The medical device sector is shaped by clinical evidence requirements, reimbursement arrangements, regulatory review and hospital capital budgets. Purchases of MR-compatible intervention systems may require changes to hospital workflows. The company’s financial statements therefore need to be read alongside installation progress and procedure volumes rather than treating regulatory milestones as immediate revenue.

Risks to Consider

Product approvals are specific to devices and indications, and further U.S. submissions remain dependent on regulatory review and clinical evidence. Trial enrolment or site activation delays could alter development timetables. Hospital purchasing cycles and installation requirements can postpone commercial revenue. The company also faces manufacturing, compatibility, clinician training and supply-chain execution risks.

The group remained loss-making in the June quarter, so spending levels and cash requirements warrant ongoing attention. Its operations also have currency exposure because financial results are reported in U.S. dollars while its ASX-traded securities are priced in Australian dollars. Middle East deployment timing was described as uncertain in the August quarterly update.

What to Watch Next

The next measurable indicators include delivery and commissioning at the first U.S. customer site, additional NorthStar sales, and commercial conversion of hospitals using compatible equipment. Investors can also follow completion of VISABL-AFL enrolment and the subsequent final premarket approval module for the Vision-MR Ablation Catheter.

Imricor Medical Systems (ASX:IMR) has also identified European site activity, regulatory decisions on additional equipment and the cadence of cash usage as operational monitoring points. Later quarterly disclosures will show whether new installations translate into recognised product revenue and recurring consumable demand.

Key Insights

Imricor’s 2026 disclosures document a transition from regulatory groundwork toward initial U.S. commercial deployment. The first customer announcement and product clearances sit alongside modest June-quarter revenue and continued operating cash outflows. Cash resources increased following the placement, but deployment, regulatory completion and revenue conversion remain key variables in evaluating subsequent operating reports.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.